October 26th, 2016 by paulineaitken



International advanced wound care and dermatology business Crawford Healthcare has announced its headline half-year figures, recording global revenue of £13.0 million for the six months ended 30th September 2016, a 19 per cent increase on the comparable period last year (2015: £11.0 million).

The performance has been driven by continued underlying growth for the group’s UK business alongside exceptional growth in the group’s international activity, notably the US, where dollar revenues from Crawford’s North American subsidiary for the six month period more than doubled compared with the six months ended 30 September 2015.

The US growth reflects increasing traction for the Group’s class-leading wound care products, positively impacted by access to new group purchasing organisation contracts and Crawford’s listing on the Federal Supply Schedule,  announced earlier this year. The Group’s in-house sales team now has access to approximately 70 per cent of hospitals in the US.

Crawford’s international success has been recognised and celebrated here domestically, with the Group securing its first ever Queen’s Award for Enterprise (International Trade), as well as being named the UK’s largest SME wound care business, climbing to fourth in the overall market* and maintaining its position as the fastest growing advanced wound care company in the UK*.

Crawford Healthcare CEO Richard Anderson commented: “As anticipated, we’ve enjoyed a really strong first six months for 2016/17, and we are well set to exceed expectations for the full year. The success of our wound care brands – now entirely owned and developed by Crawford – goes to show the quality of the Health Care and Life Sciences industry in Cheshire and the North West. Like many others in the region, we’re enjoying tremendous success overseas and showing how our market-led approach to commercialisation of our intellectual property and know-how can lead international thinking and practice in healthcare.

“For example, our proprietary silver-based OxysaltTM technology is enabling a number of our strategically important brands to compete with, and clinically outperform, global leading brands. As a result, we’re challenging and outrunning huge international operators in some of the largest global wound care product categories.”

Having enjoyed 41 per cent compound average annual growth in sales over the last three years, Crawford now employs over 130 people across its UK and international team.

Anderson concluded: “Developing and marketing truly unique products simply wouldn’t be possible without the team we have assembled and the sales approach we have adopted. Our results are testament to the endeavours of our people, and we look forward to continuing momentum across the business.”